Davern Capital Partners
Latest statistics and disclosures from Davern Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BNTX, ROIV, RPRX, IONS, INSM, and represent 55.66% of Davern Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: BNTX (+$42M), INSM (+$40M), ROIV (+$38M), RPRX (+$36M), ALNY (+$34M), IONS (+$33M), REGN (+$30M), VERA (+$21M), GPCR (+$17M), MLYS (+$11M).
- Started 3 new stock positions in AVTX, ALNY, VERA.
- Reduced shares in these 7 stocks: PFE (-$45M), ARGX (-$26M), LLY (-$25M), ABVX (-$8.7M), NTRA (-$6.8M), VRDN (-$5.9M), LEGN.
- Sold out of its positions in ABVX, ARGX, LLY, PFE, VRDN.
- Davern Capital Partners was a net buyer of stock by $198M.
- Davern Capital Partners has $587M in assets under management (AUM), dropping by 60.90%.
- Central Index Key (CIK): 0002003147
Tip: Access up to 7 years of quarterly data
Positions held by Davern Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Davern Capital Partners
Davern Capital Partners holds 15 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Biontech Se Sponsored Ads (BNTX) | 12.0 | $70M | +147% | 755k | 93.05 |
|
| Roivant Sciences SHS (ROIV) | 11.7 | $68M | +121% | 1.9M | 35.39 |
|
| Royalty Pharma Shs Class A (RPRX) | 11.0 | $65M | +122% | 1.2M | 56.07 |
|
| Ionis Pharmaceuticals (IONS) | 10.8 | $63M | +106% | 799k | 79.29 |
|
| Insmed Com Par $.01 (INSM) | 10.2 | $60M | +206% | 560k | 106.62 |
|
| Regeneron Pharmaceuticals (REGN) | 9.8 | $58M | +106% | 93k | 623.54 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 5.9 | $34M | -9% | 1.2M | 28.88 |
|
| Alnylam Pharmaceuticals (ALNY) | 5.8 | $34M | NEW | 113k | 301.03 |
|
| Natera (NTRA) | 5.5 | $32M | -17% | 119k | 271.45 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 4.1 | $24M | +252% | 446k | 53.67 |
|
| Mineralys Therapeutics (MLYS) | 4.0 | $23M | +92% | 859k | 26.98 |
|
| Vera Therapeutics Cl A (VERA) | 3.6 | $21M | NEW | 499k | 42.91 |
|
| Generate Biomedicines Com Shs (GENB) | 2.4 | $14M | +39% | 825k | 16.87 |
|
| Procept Biorobotics Corp (PRCT) | 1.8 | $11M | +77% | 465k | 22.58 |
|
| Avalo Therapeutics Com New (AVTX) | 1.5 | $8.7M | NEW | 469k | 18.48 |
|
Past Filings by Davern Capital Partners
SEC 13F filings are viewable for Davern Capital Partners going back to 2025
- Davern Capital Partners 2026 Q2 filed Aug. 13, 2026
- Davern Capital Partners 2026 Q1 filed May 14, 2026
- Davern Capital Partners 2025 Q4 filed Feb. 13, 2026